Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | PGK2 | P07205 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20536453 | 0.86 | PGK1 (0.46) | PGK1PGK2HDAC1HDAC6 | |
| SCHEMBL4848422 | 0.81 | PGK1 (0.44) | PGK1PGK2 | |
| SCHEMBL20536064 | 0.80 | PGK1 (0.38) | PGK1PGK2HDAC1HDAC6 | |
| SCHEMBL18758400 | 0.79 | PPARD (0.39) | HDAC1HDAC6 | |
| SCHEMBL8121663 | 0.77 | PGK1 (0.41) | PGK1PGK2HDAC1HDAC6 | |
| SCHEMBL20535736 | 0.75 | PGK1 (0.34) | PGK1PGK2HDAC1HDAC6 | |
| SCHEMBL20536570 | 0.74 | PGK1 (0.39) | PGK1PGK2 | |
| SCHEMBL25426497 | 0.73 | PGK1 (0.47) | PGK1PGK2 | |
| SCHEMBL3556536 | 0.73 | PGK1 (0.47) | PGK1PGK2 | |
| SCHEMBL20536551 | 0.72 | HDAC1 (0.31) | PGK1PGK2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| EP-3609538-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | William Marsh Rice University (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018191394-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | EPOR, EZR, CD47 | PGK1 4481/4885PGK2 3836/4885HDAC1 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.